Cardiovascular effects of oral MS drug Gilenya transient

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Cardiovascular effects of oral MS drug Gilenya transient

Postby MSUK » Thu May 19, 2011 3:17 am

Cardiovascular effects of oral MS drug Gilenya mostly transient

Image

The first approved oral medication for multiple sclerosis causes transient reductions in heart rate and atrioventricular conduction and a sustained increase in blood pressure, according to investigators who analyzed pooled data from two phase III trials.

The cohorts from the two phase III clinical trials of fingolimod (Gilenya) for relapsing-remitting muscular sclerosis involved 854 patients treated with the currently approved dosage offingolimod (0.5 mg/day), 849 patients on a higher dosage (1.25 mg/day), 418 patients on placebo, and 431 patients treated with weekly intramuscular injections of 30 mcg interferon beta-1a (Avonex) for 1-2 years.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2142
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service